Join the Discussion: Dealmaking, Innovation and Geopolitics in Pharma
BIO-Europe took place last week in Stockholm. It’s one of the last big biopharma events of the year and a great time to take stock of where the industry stands as the new year approaches. I was at the convention, taking part in a fireside chat to discuss global innovation trends. Also featuring on the […]
Out-Licencing Strategies: How to Secure the Right Partner
When a biotech or biopharma’s flagship asset is ready for out-licensing, which strategies will get it noticed by the right partners? To gain the attention of larger players, companies need to present clear evidence of their asset’s efficacy and market potential, along with a realistic understanding of the types of deals they can secure. Leveraging […]
Five Steps to Refining Your In-Licencing Strategy
For pharma companies, biotech assets present significant opportunities to strengthen pipelines with reduced risk. However, with such a vast ecosystem, identifying the right assets that align with your strategy can be a challenge. Whether the dealmaking goal is a quick win in a major market or securing an innovative product early, finding the most valuable […]
In Case You Missed It: Three Things we Learned in our Dealmaking Trends Webinar
If there’s one thing that the experts at Evaluate love, it’s rummaging around in data to identify trends in the pharma market. One area that is always fascinating to explore is dealmaking trends – and that’s just what my colleagues Ben Folwell and Duncan Sweeney did during our recent webinar, “Licence Drivers: Trends in Pharma […]
2024 Dealmaking: What’s the Score?
Volume is up but value is down. That’s the headline of the dealmaking scene for the first half of 2024. There’s not been a mega-merger in the vein of 2023’s Pfizer/Seagen deal, though the Novo/Catalent deal aimed at boosting supplies of the semaglutide products Ozempic and Wegovy is certainly notable. Even so, the 18% increase […]
In Case You Missed It: Three Things we Learned in our World Preview Webinar
Evaluate’s annual World Preview report is a must-read for many in the pharma industry. Each year, we pull together some of our key pharma forecasts to build a picture of the future of this ever-changing market, from the biggest drugs and players, to the therapy areas in growth or decline. The report is excellent (not […]
Who’s winning in the battle for efficient capital deployment?
Over the last ten years, large pharma companies have spent an average of $120bn across R&D and business development investments. The net result? Portfolios worth approximately $210bn, according to Evaluate’s net present value (NPV) methodology. However, within these averages lie dramatically diverging performances, highlighting the challenges of deploying capital efficiently. Overall company performance is heavily […]
What’s Behind Pharma’s Growth Boost?
One of the milestones in the Evaluate year is the publication of our annual World Preview report, now in its 17th year. If you’re not familiar with the piece, it’s a deep dive into the state of the biopharma market, using Evaluate’s pharma forecasts to uncover key trends, challenges and drivers of growth (or indeed […]
Neurology’s Renewal
In the realm of healthcare, neurology is experiencing a revival, marked by notable clinical advancements, increased deal activity, and a resurgence of interest from pharmaceutical giants. While perhaps not as widely discussed as topics like obesity, neuroscience’s return to the spotlight is evident through various indicators, including rising deal numbers and significant mergers and acquisitions. […]
What’s the Deal? Navigating the Complex World of Pharma Business Development
2024 has the potential to be a year full of partnering opportunities, driven by the much-discussed patent cliff as some of the biggest-selling drugs in history are set to lose exclusivity by 2028. Perhaps as much as 6% of the nearly $1.6 trillion overall drug market might be at risk and while this isn’t Big […]
